Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Nonlinear biomarker interactions in conversion from Mild Cognitive Impairment to Alzheimer’s disease

Sebastian G. Popescu, Alex Whittington, Roger N. Gunn, Paul M. Matthews, Ben Glocker, David J Sharp, View ORCID ProfileJames H Cole, for the Alzheimer’s Disease Neuroimaging Initiative
doi: https://doi.org/10.1101/19002378
Sebastian G. Popescu
1Computational, Cognitive & Clinical Neuroimaging Laboratory, Division of Brain Sciences, Imperial College London, London, UK
5UK Dementia Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Whittington
1Computational, Cognitive & Clinical Neuroimaging Laboratory, Division of Brain Sciences, Imperial College London, London, UK
2Invicro Ltd, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger N. Gunn
2Invicro Ltd, London, UK
3Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, UK
4Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul M. Matthews
4Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK
5UK Dementia Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Glocker
5UK Dementia Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J Sharp
1Computational, Cognitive & Clinical Neuroimaging Laboratory, Division of Brain Sciences, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H Cole
1Computational, Cognitive & Clinical Neuroimaging Laboratory, Division of Brain Sciences, Imperial College London, London, UK
7Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James H Cole
  • For correspondence: james.cole@kcl.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The multi-faceted nature of Alzheimer’s disease means that multiple biomarkers (e.g., amyloid-β, tau, brain atrophy) can contribute to the prediction of clinical outcomes. Machine learning methods are a powerful way to identify the best approach to this prediction. However, it has been difficult previously to model nonlinear interactions between biomarkers in the context of predictive models. This is important as the mechanisms relating these biomarkers to the disease are inter-related and nonlinear interactions occur. Here, we used Gaussian Processes to model nonlinear interactions when combining biomarkers to predict Alzheimer’s disease conversion in 48 mild cognitive impairment participants who progressed to Alzheimer’s disease and 158 stable (over three years) people with mild cognitive impairment. Measures included: demographics, APOE4 genotype, CSF (amyloid-β42, total tau, phosphorylated tau), neuroimaging markers of amyloid-β deposition ([18F]florbetapir) or neurodegeneration (hippocampal volume, brain-age). We examined: (i) the independent value each biomarker has in predicting conversion; and (ii) whether modelling nonlinear interactions between biomarkers improved prediction performance.

Despite relatively high correlations between different biomarkers, our results showed that each measured added complementary information when predicting conversion to Alzheimer’s disease. A linear model predicting MCI group (stable versus progressive) explained over half the variance (R2 = 0.51, P < 0.001); the strongest independently-contributing biomarker was hippocampal volume (R2 = 0.13). Next, we compared the sensitivity of different models to progressive MCI: independent biomarker models, additive models (with no interaction terms), nonlinear interaction models. We observed a significant improvement (P < 0.001) for various two-way interaction models, with the best performing model including an interaction between amyloid-β-PET and P-tau, while accounting for hippocampal volume (sensitivity = 0.77).

Our results showed that closely-related biomarkers still contribute uniquely to the prediction of conversion, supporting the continued use of comprehensive biological assessments. A number of interactions between biomarkers were implicated in the prediction of Alzheimer’s disease conversion. For example, the interaction between hippocampal atrophy and amyloid-deposition influences progression to Alzheimer’s disease over and above their independent contributions. Importantly, nonlinear interaction modelling shows that although for some patients adding additional biomarkers may add little value (i.e., when hippocampal volume is high), but for others (i.e., with low hippocampal volume) further invasive and expensive testing is warranted. Our Gaussian Processes framework enables visual examination of these nonlinear interactions, allowing projection of individual patients into biomarker ‘space’, providing a way to make personalised healthcare decisions or stratify subsets of patients for recruitment into trials of neuroprotective interventions.

Competing Interest Statement

JHC is a scientific advisor to and shareholder in Brain Key, a medical image analysis software company. PMM acknowledges consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or speakers' honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera. He is a member of the Scientific Advisory Board to the Board of Ipsen Pharmaceuticals.

Funding Statement

All data used for the preparation of this article was obtained from ADNI and are publicly-available. For up-to-date information, see www.adni-info.org. Sebastian Popescu is funded by an EPSRC Centre for Doctoral Training studentship award to Imperial College London. James Cole is funded by a UKRI Innovation Fellowship. PMM acknowledges generous personal and research support from the Edmond J Safra Foundation and Lily Safra, an NIHR Senior Investigator Award and the UK Dementia Research Institute.

Author Declarations

All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.

Not Applicable

I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.

Yes

Data Availability

All data used for the preparation of this article was obtained from ADNI and are publicly-available. For up-to-date information, see www.adni-info.org. Our statistical analysis code is available online (https://github.com/SebastianPopescu/nonlinear_interaction_GPs).

http://www.adni-info.org

https://github.com/SebastianPopescu/nonlinear_interaction_GPs

  • Abbreviations

    AUC
    Area under the receiver operating characteristic curve
    ADNI
    Alzheimer’s Disease Neuroimaging Initiative
    Brain-PAD
    Brain-predicted age difference
    MCI
    Mild Cognitive Impairment
    P-tau
    phosphorylated-tau
    SUVR
    Standardized uptake value ratios
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted August 02, 2019.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Nonlinear biomarker interactions in conversion from Mild Cognitive Impairment to Alzheimer’s disease
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Nonlinear biomarker interactions in conversion from Mild Cognitive Impairment to Alzheimer’s disease
    Sebastian G. Popescu, Alex Whittington, Roger N. Gunn, Paul M. Matthews, Ben Glocker, David J Sharp, James H Cole, for the Alzheimer’s Disease Neuroimaging Initiative
    medRxiv 19002378; doi: https://doi.org/10.1101/19002378
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Nonlinear biomarker interactions in conversion from Mild Cognitive Impairment to Alzheimer’s disease
    Sebastian G. Popescu, Alex Whittington, Roger N. Gunn, Paul M. Matthews, Ben Glocker, David J Sharp, James H Cole, for the Alzheimer’s Disease Neuroimaging Initiative
    medRxiv 19002378; doi: https://doi.org/10.1101/19002378

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Neurology
    Subject Areas
    All Articles
    • Addiction Medicine (215)
    • Allergy and Immunology (495)
    • Anesthesia (106)
    • Cardiovascular Medicine (1096)
    • Dentistry and Oral Medicine (196)
    • Dermatology (141)
    • Emergency Medicine (274)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
    • Epidemiology (9766)
    • Forensic Medicine (5)
    • Gastroenterology (480)
    • Genetic and Genomic Medicine (2308)
    • Geriatric Medicine (222)
    • Health Economics (462)
    • Health Informatics (1558)
    • Health Policy (735)
    • Health Systems and Quality Improvement (603)
    • Hematology (236)
    • HIV/AIDS (503)
    • Infectious Diseases (except HIV/AIDS) (11641)
    • Intensive Care and Critical Care Medicine (617)
    • Medical Education (237)
    • Medical Ethics (67)
    • Nephrology (257)
    • Neurology (2142)
    • Nursing (134)
    • Nutrition (336)
    • Obstetrics and Gynecology (426)
    • Occupational and Environmental Health (517)
    • Oncology (1176)
    • Ophthalmology (364)
    • Orthopedics (128)
    • Otolaryngology (220)
    • Pain Medicine (146)
    • Palliative Medicine (50)
    • Pathology (311)
    • Pediatrics (695)
    • Pharmacology and Therapeutics (300)
    • Primary Care Research (267)
    • Psychiatry and Clinical Psychology (2180)
    • Public and Global Health (4655)
    • Radiology and Imaging (777)
    • Rehabilitation Medicine and Physical Therapy (457)
    • Respiratory Medicine (623)
    • Rheumatology (274)
    • Sexual and Reproductive Health (225)
    • Sports Medicine (210)
    • Surgery (251)
    • Toxicology (43)
    • Transplantation (120)
    • Urology (94)